Oppenheimer Initiates Coverage on Palantir, Raises Target Price to $200

Several key updates have been made to analyst ratings for various US stocks. Among them is Palantir, which has been initiated on by Oppenheimer's Martin Yang with a buy rating and a target price of $200.

This decision was announced alongside several other changes in analyst ratings. For instance, Evercore analyst Elizabeth Anderson CFA maintained UnitedHealth (UNH.US) with a buy rating but increased its target price from $400 to $480. The same analyst also adjusted her target price for ConocoPhillips (COP.US) upward by $16.

UBS's Josh Silverstein, meanwhile, maintained his buy rating on Marathon Petroleum (MPC.US), raising the company's target price from $265 to $453. However, some stocks saw their ratings downgraded. For example, Wells Fargo analyst Jason Kupferberg downgraded Accenture (ACN.US) to a hold rating while maintaining its target price at $194.

Morgan Stanley's Joe Laetsch also maintained his buy rating on Marathon Petroleum but bumped up the company's target price by nearly 71% from $265 to $453. The analyst's decision was one of several made today as major financial institutions continue to monitor US stock market performance.